Abstract: Described herein is a method of preparing an unbiased library of phage variants, comprising (a) preparing a population of “acceptor phage”; (b) removing an endogenous target gene and inserting gene variants into the acceptor phage genomes; (c) enriching the recombined phages; and (d) expressing the library for selection. The acceptor phage is a lytic phage comprising a synthetic genome wherein the target gene of interest is flanked by recombinase sites. The acceptor phage infects a first host bacteria expressing a recombination plasmid facilitating recombination. The phages then infect a second host bacteria expressing a counterselection system that accumulates recombined phage variants and selecting against non-recombined phages. The accumulated phage variants infect a third host bacteria. The phage library may then be sequenced and characterized.

Abstract: Described herein are pharmaceutical compositions, medicaments and methods for providing effective immunomodulation with chimeric proteins including FasL moieties for selective and long-lasting regulation of the immune response.

Abstract: Compositions and methods for treating a medical condition are provided. Accordingly, there is provided a composition comprising a polypeptide comprising a GnRH receptor binding protein and a polynucleotide coding a therapeutic agent, wherein said polypeptide is in association with said polynucleotide via a linker comprising a cleavage motif that can be cleaved by a proteolytic enzyme secreted by a cell expressing said GnRH receptor. Also provided is a nucleic acid construct comprising a nucleic acid sequence encoding a fusion protein comprising a DNA binding domain (DBD) of a transcription factor that binds a regulatory region of a gonadotropin gene attached to a chromatin modifying domain that represses transcription upon association with the DBD. Also provided are methods of use thereof.

Abstract: The present invention relates to a novel biomarker for diagnosing cancer, and a use thereof. STC1, a novel biomarker for diagnosing or predicting the prognosis of cancer according to the present invention, was found to be related to poor prognosis of cancer patients according to the expression level, and was found to be overexpressed in various cancer cell lines. In addition, STC1 was found to be a biomarker related to the proliferation, invasion, and migration (metastasis) of cancer cells. In addition, it was found that STC1 is detected in the serum or urine of bladder cancer patients, and can be effectively used for diagnosing and predicting the prognosis of bladder cancer by identifying differences in expression according to the patient's clinical stage.

Abstract: The present invention relates to a pharmaceutical composition comprising a population of cells including irradiated hematopoietic stem cells, and a method for producing the pharmaceutical composition, specifically, a pharmaceutical composition for treating an ischemic disease, comprising a population of cells including irradiated hematopoietic stem cells, wherein the irradiation is irradiation at 50 Gy or less, and a method for producing the pharmaceutical composition.

Abstract: Provided are a biodegradable polymer scaffold including bioactive materials and methods of manufacturing the same. The biodegradable polymer scaffold, preventing inflammatory responses caused by acidic substances produced during a degradation process, has easily controllable mechanical strength, and includes bioactive materials derived from cells of target tissues, and thus may induce tissue regeneration more effectively.

Abstract: A method to inhibit neutrophil recruitment to damaged tissue, thereby inhibiting inflammation in a subject. The method includes administering to an anti-inflammatory amount of a myeloid-derived growth factor (“MYDGF”). Also disclosed are corresponding pharmaceutical compositions of matter containing the MYDGF.

Abstract: Provided is a method for providing information on chronic urticaria and, more specifically, the provided is a method for diagnosing chronic urticaria by measuring an allergen-specific IgE antibody for a vesicle derived from Acinetobacter bacteria; a diagnostic composition using the same; and the like.

Abstract: The present disclosure relates to a silicon anode, a method for manufacturing the same, and a battery including the same. Particularly, the silicon anode improves the interfacial contact between the silicon anode and a sulfide-based solid electrolyte layer, and thus the interfacial contact can be maintained uniformly during lithiation even under low pressure, and high delithiation capacity and coulombic efficiency can be realized.

Abstract: Disclosed are a ferroelectric-based semiconductor device and a method of manufacturing the same. The ferroelectric-based semiconductor device includes a substrate used as a gate; a gate oxide film formed on the substrate; a channel formed on the gate oxide film; and a source/drain formed on the channel, and the semiconductor device is plasma treated. The ferroelectric-based semiconductor device may be used as a memory device and an artificial synaptic device.

Abstract: Various embodiments of the present disclosure relate to a system for analyzing an operation cause of a crash safety control logic of a vehicle an operation method thereof.

Abstract: A composition for forming polyurethane foam including a polyol mixture containing two or more polyols having different melting points, an isocyanate compound, and a blowing agent, wherein the two or more polyols are respectively included in the same weight ratio. A foam for a vehicle seat including a polyurethane foam manufactured from the composition for forming polyurethane foam described above. A method of manufacturing a foam for a vehicle seat including manufacturing a polyurethane foam from the composition for forming polyurethane foam described above, and coating a coating layer composition containing 1 to 5 wt % of carbon nanotubes on at least one surface of the polyurethane foam. A vehicle seat including the foam for a vehicle seat described above.

Abstract: Provided are diagnosis and treatment methods of autism spectrum disorder, based on an activity regulation mechanism of quiescent neural stem cells, and use thereof.

Abstract: A biochip includes a first chip body configured to culture cells or biological tissues inside a first channel formed in the first chip body and including a first contact channel portion formed on one side communicating with the channel to be in close contact with a second contact channel portion of a second chip body; and a second chip body configured to culture heterogeneous cells or biological tissues, which are different from the cells or biological tissues cultured in the first chip body, in a second channel formed inside the second chip body and including the second chip body which is formed on a side facing the first chip body and forms the second contact channel portion in close contact with the first contact channel portion of the first chip body.

Abstract: The present invention relates to a method for creating a neural network model which can imitate retouching styles of a plurality of experts, and creating a black-and-white photo which gives aesthetics by inputting a color photo into the neural network model.

Abstract: Disclosed are a federated learning method and device using device clustering. The federated learning method includes obtaining an arbitrary client group including some clients as a result of performing clustering on a plurality of clients; determining one of the some clients as a leader client based on a centroid associated with the clustering, wherein the leader client receives data associated with at least one parameter of a pre-trained model from each of the some clients; determining at least one client among the some clients as a target client based on an amount of computing resources of the pre-trained model and a training loss of the pre-trained model; and receiving some data associated with at least one parameter of the model of the target client from the leader client, wherein the some data is included in the data.

Abstract: The present disclosure relates to an upstream of mTORC2 (UT2) gene-deficient mouse model and a method of screening therapeutic agents for myeloid leukemia using the same, wherein it was found that the onset of myeloid leukemia and proliferation of myeloid leukemia cells were more facilitated in UT2 gene-deficient mice and UT2 genetic scissor (Cripsr/Cas9)-deficient myeloid leukemia cell lines. In addition, it was found that the survival rate of patients with low expression of UT2 was low in myeloid leukemia patients, while expression of UT2 was low in cells of actual myeloid leukemia patients.

Abstract: Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

Abstract: The present invention is directed to a cyclic polypeptide having ubiquitin binding affinity (KD) of 0.1-100 nM. Further provided are methods for reducing deubiquitination activity of a cell, and for treating cancer in a subject in need thereof.

Abstract: A NOX storage catalyst includes CHA zeolite, a transition metal ion-exchanged in the CHA zeolite, and a rare earth metal that is different the transition metal and is supported on the CHA zeolite. A method for preparing a NOX storage catalyst includes preparing a synthetic mother liquid including a zeolite raw material as a source of silica and alumina, a structure-inducing material, a complexing material, and a solvent, reacting the synthetic mother liquid to prepare a CHA zeolite, and supporting a transition metal and a rare earth metal that is different from the transition metal on the prepared CHA zeolite.